Bessemer Group Inc. trimmed its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 2.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,805,630 shares of the exchange traded fund’s stock after selling 47,602 shares during the quarter. Bessemer Group Inc. owned about 2.83% of SPDR S&P Biotech ETF worth $230,633,000 as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of XBI. Dynamic Wealth Strategies LLC grew its position in shares of SPDR S&P Biotech ETF by 3.8% in the fourth quarter. Dynamic Wealth Strategies LLC now owns 2,201 shares of the exchange traded fund’s stock valued at $268,000 after purchasing an additional 80 shares in the last quarter. Capital Investment Advisory Services LLC increased its holdings in shares of SPDR S&P Biotech ETF by 4.0% in the fourth quarter. Capital Investment Advisory Services LLC now owns 2,123 shares of the exchange traded fund’s stock valued at $259,000 after purchasing an additional 81 shares during the last quarter. Commerce Bank lifted its position in SPDR S&P Biotech ETF by 2.8% during the fourth quarter. Commerce Bank now owns 3,260 shares of the exchange traded fund’s stock worth $397,000 after buying an additional 90 shares in the last quarter. Compass Ion Advisors LLC lifted its position in SPDR S&P Biotech ETF by 2.6% during the fourth quarter. Compass Ion Advisors LLC now owns 3,886 shares of the exchange traded fund’s stock worth $474,000 after buying an additional 97 shares in the last quarter. Finally, Moors & Cabot Inc. lifted its position in SPDR S&P Biotech ETF by 3.8% during the third quarter. Moors & Cabot Inc. now owns 2,717 shares of the exchange traded fund’s stock worth $272,000 after buying an additional 100 shares in the last quarter.
SPDR S&P Biotech ETF Stock Performance
NYSEARCA XBI opened at $152.00 on Friday. The stock’s fifty day moving average is $142.06 and its two-hundred day moving average is $132.23. The firm has a market capitalization of $10.34 billion, a P/E ratio of 11.47 and a beta of 0.82. SPDR S&P Biotech ETF has a fifty-two week low of $84.39 and a fifty-two week high of $165.71.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Recommended Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
